Metabolic
Tirzepatide
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US and EU.
Quick start
Tirzepatide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 2.5–15 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Timing
- Once weekly on the same day; time of day is flexible.
- What people report
- Appetite changes are often noticed early; the amount is stepped up gradually to limit gastrointestinal effects.
- Time to steady level
- ~25.0 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
- Cycle length
- titrated over months
- Break between
- n/a — titrated, not cycled Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C225H348N48O68
- Mol. weight
- 4,813.53 Da
- CAS
- 2023788-19-2
- PubChem CID
- 166567236
External references
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Tirzepatide describe 2.5–15 mg per administration. Descriptive only, not a recommendation.
Dosing schedule
How Tirzepatide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Starting step to limit gastrointestinal effects. | 2.5 mg | Once weekly | SubQ |
| Weeks 5–8 | 5 mg | Once weekly | SubQ |
| Weeks 9–12 | 7.5 mg | Once weekly | SubQ |
| Weeks 13–16 | 10 mg | Once weekly | SubQ |
| Week 17+Step up in 2.5 mg increments no sooner than every 4 weeks. | 12.5–15 mg | Once weekly | SubQ |
What it can be combined with
How Tirzepatide is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
- RetatrutideOverlapping GLP-1 receptor agonism; stacking incretin agonists compounds gastrointestinal load without adding a mechanism in research reports.Avoid combination
- SemaglutideTwo incretin agonists on the same receptor — the combination adds gastrointestinal effects, not benefit, in research reports.Avoid combination
- CagrilintideAmylin analog studied alongside incretin agonists; it deepens appetite suppression and gastrointestinal effects.Use caution
- InsulinAdditive glucose-lowering raises the hypoglycemia signal; glucose bears closer monitoring when combined.Monitor combination
- Oral medicationsSlowed gastric emptying can alter oral-drug absorption — a known caution for oral contraceptives in particular.Requires timing
- MetforminFrequently co-administered in studies with no adverse interaction reported.Commonly combined
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- SURMOUNT-1 (Jastreboff et al., NEJM 2022)Weekly tirzepatide 5–15 mg in obesity research.